On September 29, 2026, Deloitte published "How a $527 billion growth opportunity in women's health can improve health outcomes," a modelling report estimating that moving U.S. women's healthcare from reactive treatment to proactive, "life-stage-aware" care could create $527 billion in additional potential spending on U.S. women's health in 2030, compared with the modelled baseline trajectory. The analysis adapts Deloitte's actuarial Future of Health approach, built on five years of medical and pharmacy claims data covering nearly 60 million lives, and compares a baseline scenario against one that assumes prevention, earlier detection and better disease management.

Why It Matters

For sexual wellness and femtech founders, the notable figure is the smallest one. Pelvic, reproductive and hormonal care, the bucket that holds pelvic-floor devices, menopause sexual-health products, vaginal-microbiome testing and hormone therapy, comes in at $21 billion, well behind musculoskeletal, cardiovascular and brain health. That doesn't make it a small market. It does mean the largest "women's health" dollars in Deloitte's model sit in chronic-disease categories where sextech-adjacent companies rarely play. Expect midlife-focused platforms to reposition around bone, heart and cognition, with sexual health bundled in rather than leading. The report arrives in a week full of menopause signals: congressional pressure over the estradiol-patch shortage, a Which? finding that pricey menopause supplements underperform a 6p multivitamin, and continued Series B money flowing to women's-health diagnostics. A big-four consultancy putting a half-trillion-dollar label on the category gives investors and payers a reference point. It also sets a very high bar that clinical evidence will need to clear.

The report screened 22 care areas and singled out four where, in Deloitte's words, unmet clinical need and market demand "may converge": brain health, pelvic health, cardiovascular care, and musculoskeletal/autoimmune conditions. Chief Healthcare Executive, which interviewed authors Jen Radin and Andy Davis, broke the four out by size: musculoskeletal/autoimmune/inflammatory at $56 billion, cardiovascular/stroke at $49 billion, neurological at $44 billion, and pelvic/reproductive/hormonal at $21 billion. Deloitte also models that in a long-run prevention scenario women's health span could increase by up to 20 years.

The demographic driver is menopause. Per Chief Healthcare Executive, between 60 and 70 million American women will be over 45 by 2030, many entering or nearing menopause, and women make roughly 80% of U.S. health purchasing decisions. "Women's health really represents one of the largest and most underdeveloped opportunities in the health economy today," Radin said. "But until this report, no one has actually valued the size of that."

Read the fine print before you put this number in a pitch deck. The $527 billion is modelled additional demand in one scenario, not a market-size forecast or an addressable-revenue figure, and the release itself uses conditional language throughout ("may create," "could potentially increase").

Sources

Update — 2026-09-30

Initial entry — story first created.